BG104802A - Скрининг и конструиране на лиганди чрез рентгеноструктурен анализ - Google Patents

Скрининг и конструиране на лиганди чрез рентгеноструктурен анализ Download PDF

Info

Publication number: BG104802A
Authority: BG; Bulgaria
Prior art keywords: ligand; target biomolecule; crystal; target; biomolecule
Prior art date: 1998-03-06

Application number

BG104802A

Other languages

Bulgarian (bg)

English (en)

Inventor

Vicki Nienaber

Jonathon Greer

Celerino Abad-Zapatero

Daniel Norbeck

Original Assignee

Abbott Laboratories

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-06

Filing date

2000-09-27

Publication date

2001-04-30

2000-09-27 Application filed by Abbott Laboratories filed Critical Abbott Laboratories

2001-04-30 Publication of BG104802A publication Critical patent/BG104802A/bg

Links

239000003446 ligand Substances 0.000 title claims abstract description 141
238000012216 screening Methods 0.000 title claims description 49
238000013461 design Methods 0.000 title abstract description 4
238000002424 x-ray crystallography Methods 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 claims abstract description 166
238000000034 method Methods 0.000 claims abstract description 128
239000013078 crystal Substances 0.000 claims abstract description 106
230000008569 process Effects 0.000 claims abstract description 47
238000012360 testing method Methods 0.000 claims abstract description 23
230000000593 degrading effect Effects 0.000 claims abstract 2
230000027455 binding Effects 0.000 claims description 81
239000000203 mixture Substances 0.000 claims description 75
239000012634 fragment Substances 0.000 claims description 16
108090000765 processed proteins & peptides Proteins 0.000 claims description 11
102000004196 processed proteins & peptides Human genes 0.000 claims description 8
238000002288 cocrystallisation Methods 0.000 claims description 7
229920001184 polypeptide Polymers 0.000 claims description 7
230000015572 biosynthetic process Effects 0.000 claims description 4
230000015556 catabolic process Effects 0.000 claims description 4
238000006731 degradation reaction Methods 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 2
230000004071 biological effect Effects 0.000 abstract description 10
238000002791 soaking Methods 0.000 abstract 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 46
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 46
229960005356 urokinase Drugs 0.000 description 45
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 38
108090000623 proteins and genes Proteins 0.000 description 37
102000004169 proteins and genes Human genes 0.000 description 27
210000004027 cell Anatomy 0.000 description 24
235000018102 proteins Nutrition 0.000 description 22
239000000872 buffer Substances 0.000 description 17
239000000243 solution Substances 0.000 description 17
108020004414 DNA Proteins 0.000 description 15
102000053602 DNA Human genes 0.000 description 15
102000004190 Enzymes Human genes 0.000 description 14
108090000790 Enzymes Proteins 0.000 description 14
238000002441 X-ray diffraction Methods 0.000 description 14
238000002425 crystallisation Methods 0.000 description 14
229940088598 enzyme Drugs 0.000 description 14
238000002474 experimental method Methods 0.000 description 14
230000008025 crystallization Effects 0.000 description 13
230000000694 effects Effects 0.000 description 13
239000011159 matrix material Substances 0.000 description 13
239000000047 product Substances 0.000 description 13
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
239000003814 drug Substances 0.000 description 12
239000003112 inhibitor Substances 0.000 description 12
239000013615 primer Substances 0.000 description 11
229940079593 drug Drugs 0.000 description 9
238000006467 substitution reaction Methods 0.000 description 9
239000002773 nucleotide Substances 0.000 description 8
125000003729 nucleotide group Chemical group 0.000 description 8
230000035945 sensitivity Effects 0.000 description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
239000007853 buffer solution Substances 0.000 description 7
238000001514 detection method Methods 0.000 description 7
230000012010 growth Effects 0.000 description 7
229910052739 hydrogen Inorganic materials 0.000 description 7
239000013598 vector Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 6
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
241000235648 Pichia Species 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 6
235000001014 amino acid Nutrition 0.000 description 6
150000001413 amino acids Chemical class 0.000 description 6
238000013459 approach Methods 0.000 description 6
230000001580 bacterial effect Effects 0.000 description 6
238000004364 calculation method Methods 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000001257 hydrogen Substances 0.000 description 6
238000012900 molecular simulation Methods 0.000 description 6
230000010355 oscillation Effects 0.000 description 6
239000000126 substance Substances 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
230000000007 visual effect Effects 0.000 description 6
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
108010059993 Vancomycin Proteins 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
150000007942 carboxylates Chemical group 0.000 description 5
239000012528 membrane Substances 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
229920002477 rna polymer Polymers 0.000 description 5
239000002904 solvent Substances 0.000 description 5
239000000758 substrate Substances 0.000 description 5
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 5
229960003165 vancomycin Drugs 0.000 description 5
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 5
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
241000700605 Viruses Species 0.000 description 4
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
238000010367 cloning Methods 0.000 description 4
238000010276 construction Methods 0.000 description 4
239000006184 cosolvent Substances 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
239000006166 lysate Substances 0.000 description 4
229960004452 methionine Drugs 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
229910052725 zinc Inorganic materials 0.000 description 4
239000011701 zinc Substances 0.000 description 4
GCMNJUJAKQGROZ-UHFFFAOYSA-N 1,2-Dihydroquinolin-2-imine Chemical compound C1=CC=CC2=NC(N)=CC=C21 GCMNJUJAKQGROZ-UHFFFAOYSA-N 0.000 description 3
UFVLIVCXTIGACT-UHFFFAOYSA-N 2-aminoquinolin-8-ol Chemical compound C1=CC=C(O)C2=NC(N)=CC=C21 UFVLIVCXTIGACT-UHFFFAOYSA-N 0.000 description 3
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
239000003155 DNA primer Substances 0.000 description 3
238000001712 DNA sequencing Methods 0.000 description 3
108010088842 Fibrinolysin Proteins 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
239000004365 Protease Substances 0.000 description 3
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
238000005162 X-ray Laue diffraction Methods 0.000 description 3
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
229910052921 ammonium sulfate Inorganic materials 0.000 description 3
235000011130 ammonium sulphate Nutrition 0.000 description 3
239000011324 bead Substances 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
238000002447 crystallographic data Methods 0.000 description 3
238000013480 data collection Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
238000009510 drug design Methods 0.000 description 3
229940088679 drug related substance Drugs 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
239000008103 glucose Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 3
235000018977 lysine Nutrition 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
239000012460 protein solution Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000011514 reflex Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
229910052710 silicon Inorganic materials 0.000 description 3
239000010703 silicon Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000012916 structural analysis Methods 0.000 description 3
150000003573 thiols Chemical class 0.000 description 3
238000012546 transfer Methods 0.000 description 3
ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
ZYZCALPXKGUGJI-DDVDASKDSA-M (e,3r,5s)-7-[3-(4-fluorophenyl)-2-phenyl-5-propan-2-ylimidazol-4-yl]-3,5-dihydroxyhept-6-enoate Chemical compound C=1C=C(F)C=CC=1N1C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C(C)C)N=C1C1=CC=CC=C1 ZYZCALPXKGUGJI-DDVDASKDSA-M 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
229930024421 Adenine Natural products 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
229940127007 Compound 39 Drugs 0.000 description 2
102000010911 Enzyme Precursors Human genes 0.000 description 2
108010062466 Enzyme Precursors Proteins 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
101150023810 PHO1 gene Proteins 0.000 description 2
102000013566 Plasminogen Human genes 0.000 description 2
108010051456 Plasminogen Proteins 0.000 description 2
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
101100271429 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ATP6 gene Proteins 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
101100115751 Trypanosoma brucei brucei dnaaf11 gene Proteins 0.000 description 2
MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
229960000643 adenine Drugs 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
150000003838 adenosines Chemical class 0.000 description 2
239000003463 adsorbent Substances 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
-1 ethylene- Chemical class 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
101150098537 kdsB gene Proteins 0.000 description 2
150000002611 lead compounds Chemical class 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
230000011987 methylation Effects 0.000 description 2
238000007069 methylation reaction Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
150000002894 organic compounds Chemical class 0.000 description 2
229940012957 plasmin Drugs 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000006337 proteolytic cleavage Effects 0.000 description 2
BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
239000000523 sample Substances 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000007858 starting material Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 1
JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 1
ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical group Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 description 1
KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
ZCBIFHNDZBSCEP-UHFFFAOYSA-N 1H-indol-5-amine Chemical compound NC1=CC=C2NC=CC2=C1 ZCBIFHNDZBSCEP-UHFFFAOYSA-N 0.000 description 1
PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
AHIBSEICBQMMDB-UHFFFAOYSA-N 2-aminooxypropanoic acid Chemical compound NOC(C)C(O)=O AHIBSEICBQMMDB-UHFFFAOYSA-N 0.000 description 1
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical group NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108091028026 C-DNA Proteins 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
241000425361 Chlorodium Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
238000012270 DNA recombination Methods 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
102000012545 EGF-like domains Human genes 0.000 description 1
108050002150 EGF-like domains Proteins 0.000 description 1
241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
JLXVRFDTDUGQEE-YFKPBYRVSA-N Gly-Arg Chemical compound NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N JLXVRFDTDUGQEE-YFKPBYRVSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000033229 Immune-mediated cerebellar ataxia Diseases 0.000 description 1
101150045458 KEX2 gene Proteins 0.000 description 1
241000235058 Komagataella pastoris Species 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
102000016397 Methyltransferase Human genes 0.000 description 1
108060004795 Methyltransferase Proteins 0.000 description 1
241001460678 Napo <wasp> Species 0.000 description 1
102000011931 Nucleoproteins Human genes 0.000 description 1
108010061100 Nucleoproteins Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108090000279 Peptidyltransferases Proteins 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
102000003929 Transaminases Human genes 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
VYTBPJNGNGMRFH-UHFFFAOYSA-N acetic acid;azane Chemical compound N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O VYTBPJNGNGMRFH-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001409 amidines Chemical class 0.000 description 1
229960002684 aminocaproic acid Drugs 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000002547 anomalous effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
239000003782 beta lactam antibiotic agent Substances 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
229940126208 compound 22 Drugs 0.000 description 1
229940125877 compound 31 Drugs 0.000 description 1
229940125878 compound 36 Drugs 0.000 description 1
229940125807 compound 37 Drugs 0.000 description 1
229940126540 compound 41 Drugs 0.000 description 1
229940125936 compound 42 Drugs 0.000 description 1
238000000205 computational method Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000002153 concerted effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
229940125808 covalent inhibitor Drugs 0.000 description 1
239000002577 cryoprotective agent Substances 0.000 description 1
238000012866 crystallographic experiment Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
230000029087 digestion Effects 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
229940001501 fibrinolysin Drugs 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000007667 floating Methods 0.000 description 1
GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
229960001031 glucose Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
238000013537 high throughput screening Methods 0.000 description 1
230000005661 hydrophobic surface Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
239000007788 liquid Substances 0.000 description 1
150000002669 lysines Chemical class 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000009149 molecular binding Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
WXVUCMFEGJUVTN-UHFFFAOYSA-N phenyl methanesulfonate Chemical compound CS(=O)(=O)OC1=CC=CC=C1 WXVUCMFEGJUVTN-UHFFFAOYSA-N 0.000 description 1
WVVOKXIXQQJFAE-UHFFFAOYSA-N phenylmethanesulfonic acid;hydrochloride Chemical compound Cl.OS(=O)(=O)CC1=CC=CC=C1 WVVOKXIXQQJFAE-UHFFFAOYSA-N 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical class [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
230000033885 plasminogen activation Effects 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000013014 purified material Substances 0.000 description 1
125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
108010073863 saruplase Proteins 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000008362 succinate buffer Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000010414 supernatant solution Substances 0.000 description 1
239000002344 surface layer Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
230000005469 synchrotron radiation Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
101150096103 vanX gene Proteins 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000002699 waste material Substances 0.000 description 1
239000002132 β-lactam antibiotic Substances 0.000 description 1
229940124586 β-lactam antibiotics Drugs 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/972—Plasminogen activators
- G01N2333/9723—Urokinase
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Immunology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Bioinformatics & Computational Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Crystallography & Structural Chemistry (AREA)
Materials Engineering (AREA)
Metallurgy (AREA)
Organic Chemistry (AREA)
Analysing Materials By The Use Of Radiation (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

BG104802A 1998-03-06 2000-09-27 Скрининг и конструиране на лиганди чрез рентгеноструктурен анализ BG104802A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3618498A	1998-03-06	1998-03-06
PCT/US1999/004967 WO1999045379A2 (fr)	1998-03-06	1999-03-05	Criblage et elaboration de ligands par cristallographie aux rayons x

Publications (1)

Publication Number	Publication Date
BG104802A true BG104802A (bg)	2001-04-30

Family

ID=21887121

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG104802A BG104802A (bg)	1998-03-06	2000-09-27	Скрининг и конструиране на лиганди чрез рентгеноструктурен анализ

Country Status (18)

Country	Link
US (1)	US6297021B1 (fr)
EP (1)	EP1068531B1 (fr)
JP (1)	JP2002506206A (fr)
KR (1)	KR20010041653A (fr)
CN (2)	CN100354627C (fr)
AT (1)	ATE375510T1 (fr)
AU (3)	AU2887099A (fr)
BG (1)	BG104802A (fr)
BR (1)	BR9908563A (fr)
CA (1)	CA2321968A1 (fr)
DE (1)	DE69937292T2 (fr)
HU (1)	HUP0101959A3 (fr)
IL (1)	IL137758A0 (fr)
NO (1)	NO20004433L (fr)
PL (1)	PL343264A1 (fr)
SK (1)	SK13242000A3 (fr)
TR (4)	TR200101127T2 (fr)
WO (2)	WO1999045389A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030049678A1 (en) *	1999-03-05	2003-03-13	Nienaber Vicki L.	Ligand screening and design by X-ray crystallography
US20030022383A1 (en) *	1999-04-06	2003-01-30	Uab Research Foundation	Method for screening crystallization conditions in solution crystal growth
US7247490B2 (en)	1999-04-06	2007-07-24	Uab Research Foundation	Method for screening crystallization conditions in solution crystal growth
US7214540B2 (en) *	1999-04-06	2007-05-08	Uab Research Foundation	Method for screening crystallization conditions in solution crystal growth
US7244396B2 (en)	1999-04-06	2007-07-17	Uab Research Foundation	Method for preparation of microarrays for screening of crystal growth conditions
US7250305B2 (en)	2001-07-30	2007-07-31	Uab Research Foundation	Use of dye to distinguish salt and protein crystals under microcrystallization conditions
US6630006B2 (en) *	1999-06-18	2003-10-07	The Regents Of The University Of California	Method for screening microcrystallizations for crystal formation
US20040252299A9 (en)	2000-01-07	2004-12-16	Lemmo Anthony V.	Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
US7108970B2 (en)	2000-01-07	2006-09-19	Transform Pharmaceuticals, Inc.	Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
GB0008563D0 (en)	2000-04-07	2000-05-24	Cambridge Discovery Chemistry	Investigating different physical and/or chemical forms of materials
WO2002022154A2 (fr) *	2000-09-13	2002-03-21	Praecis Pharmaceuticals Incorporated	Compositions pharmaceutiques pour medicaments a liberation prolongee
US7806980B2 (en)	2000-12-23	2010-10-05	Elan Pharmaceuticals, Inc.	Method for crystallizing human beta secretase in complex with an inhibitor
US7601528B1 (en)	2000-12-23	2009-10-13	Elan Pharmaceuticals, Inc.	Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
US7217556B1 (en)	2000-12-23	2007-05-15	Pfizer Inc	Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
US7670429B2 (en)	2001-04-05	2010-03-02	The California Institute Of Technology	High throughput screening of crystallization of materials
WO2002083938A2 (fr) *	2001-04-11	2002-10-24	Emerald Biostructures, Inc.	Procedes de criblage pour l'identification de ligands
US7384773B1 (en) *	2001-05-10	2008-06-10	Pfizer Inc	Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
US7524668B1 (en) *	2001-05-10	2009-04-28	Elan Pharmaceuticals, Inc.	Crystal of human beta secretase having monoclinic space group symmetry C2 and methods for crystallization thereof
US7130747B1 (en) *	2001-05-31	2006-10-31	Los Alamos National Security, Llc	High throughput screening of ligand binding to macromolecules using high resolution powder diffraction
IL151012A0 (en) *	2001-08-03	2003-02-12	Ribosomes Structure And Protei	Ribosomes structure and protein synthesis inhibitors
AU2002333508A1 (en) *	2001-08-22	2003-03-10	Novartis Ag	Method to identify modulators for human 3alpha-hydroxysteroid dehydrogenase
US20030211538A1 (en) *	2001-12-03	2003-11-13	Ming Luo	CAP-Gly domain structure and uses thereof
US20040171062A1 (en) *	2002-02-28	2004-09-02	Plexxikon, Inc.	Methods for the design of molecular scaffolds and ligands
US7469036B2 (en) *	2002-04-19	2008-12-23	Los Alamos National Security, Llc	Analysis of macromolecules, ligands and macromolecule-ligand complexes
US7442537B1 (en)	2002-05-10	2008-10-28	Elan Pharmaceuticals, Inc.	Crystals of unliganded beta secretase and/or beta secretase-like proteins and the use thereof
US6989392B2 (en) *	2002-06-18	2006-01-24	Abbott Laboratories	2-Aminoquinolines as melanin concentrating hormone receptor antagonists
US8019550B2 (en) *	2002-07-24	2011-09-13	Keddem Bioscience Ltd.	Drug discovery method
AU2003272548A1 (en) *	2002-09-16	2004-04-30	Plexxikon, Inc.	Crystal structure of pim-1 kinase
WO2006078228A1 (fr) *	2002-09-16	2006-07-27	Plexxikon, Inc.	Procedes de conception d'echafaudages moleculaires et de ligands
JP2006516095A (ja) *	2002-11-14	2006-06-22	ザスクリップスリサーチインスティテュート	脂肪酸アミドヒドロラーゼ（ｆａａｈ）の結晶形
ATE354096T1 (de) *	2002-12-23	2007-03-15	Astex Therapeutics Ltd	Synthese und screening von liganden mit hilfe von röntgenkristallographie
JP2007524374A (ja) *	2003-02-28	2007-08-30	プレキシコン，インコーポレーテッド	Ｐｙｋ２結晶構造および使用
WO2004092727A2 (fr) *	2003-04-11	2004-10-28	Structural Genomix, Inc.	Bibliotheques de composes et procedes de decouverte de medicaments
US20050079548A1 (en) *	2003-07-07	2005-04-14	Plexxikon, Inc.	Ligand development using PDE4B crystal structures
WO2005017533A1 (fr) *	2003-08-06	2005-02-24	Proteros Biostructures Gmbh	Procede d'identification de fragments moleculaires a faible pouvoir de liaison, aux proprietes de ligands, lesdits fragments moleculaires etant appliques sur un cristal, sous forme de microgouttes d'une solution appropriee
DE10336110B4 (de) *	2003-08-06	2008-01-03	Proteros Biostructures Gmbh	Vorrichtung und Verfahren zum Behandeln eines Proteinkristalls
WO2005028624A2 (fr) *	2003-09-15	2005-03-31	Plexxikon, Inc.	Echafaudages moleculaires pour le developpement de ligands des proteines kinases
DE10343522B4 (de) *	2003-09-19	2008-09-18	Proteros Biostructures Gmbh	Verfahren und Speichermedium zur Steuerung der Behandlung eines Kristalls mit einer Flüssigkeit
EP1899370A4 (fr) *	2005-05-12	2009-11-11	Cytopia Res Pty Ltd	Structure cristalline et son utilisation
US20090317850A1 (en) *	2008-06-20	2009-12-24	Tomoko Sunami	Crystal Structure of Human 70KD Ribosomal Protein S6 Kinase 1 Kinase Domain
CN101339167B (zh) *	2008-08-27	2011-12-14	中国药科大学	基于靶蛋白亲和选择的活性成分高通量筛选方法
DE102008049675A1 (de)	2008-09-30	2010-04-01	Markus Dr. Heinrich	Verfahren zur Herstellung von 3-Aminobiphenylen
WO2010100847A1 (fr) *	2009-03-03	2010-09-10	独立行政法人国立高等専門学校機構	Dispositif pour la cristallisation d'un biopolymère, cellule de solution pour la cristallisation d'un biopolymère, procédé pour le contrôle de l'alignement d'un biopolymère, procédé pour la cristallisation d'un biopolymère et cristal de biopolymère
CN102101886A (zh)	2009-12-18	2011-06-22	四川辉阳生命工程股份有限公司	构象改变的重组干扰素晶体、其三维结构及应用
JP5598238B2 (ja) *	2010-10-08	2014-10-01	株式会社リコー	画像形成装置
CN106033064B (zh) *	2015-03-10	2019-05-07	上海上药信谊药厂有限公司	胆维丁测定方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5112755A (en)	1982-04-15	1992-05-12	Genentech, Inc.	Preparation of functional human urokinase proteins

1999
- 1999-03-01 WO PCT/US1999/004518 patent/WO1999045389A2/fr not_active Ceased
- 1999-03-01 AU AU28870/99A patent/AU2887099A/en not_active Withdrawn
- 1999-03-05 CN CNB998058866A patent/CN100354627C/zh not_active Expired - Fee Related
- 1999-03-05 TR TR2001/01127T patent/TR200101127T2/xx unknown
- 1999-03-05 HU HU0101959A patent/HUP0101959A3/hu unknown
- 1999-03-05 TR TR2000/02572T patent/TR200002572T2/xx unknown
- 1999-03-05 DE DE69937292T patent/DE69937292T2/de not_active Expired - Fee Related
- 1999-03-05 TR TR2001/01129T patent/TR200101129T2/xx unknown
- 1999-03-05 SK SK1324-2000A patent/SK13242000A3/sk unknown
- 1999-03-05 JP JP2000534866A patent/JP2002506206A/ja active Pending
- 1999-03-05 BR BR9908563-1A patent/BR9908563A/pt not_active IP Right Cessation
- 1999-03-05 KR KR1020007009855A patent/KR20010041653A/ko not_active Withdrawn
- 1999-03-05 CN CN200710181713.2A patent/CN101221138A/zh active Pending
- 1999-03-05 AU AU29878/99A patent/AU767991B2/en not_active Ceased
- 1999-03-05 PL PL99343264A patent/PL343264A1/xx unknown
- 1999-03-05 AT AT99911174T patent/ATE375510T1/de not_active IP Right Cessation
- 1999-03-05 CA CA002321968A patent/CA2321968A1/fr not_active Abandoned
- 1999-03-05 US US09/263,904 patent/US6297021B1/en not_active Expired - Lifetime
- 1999-03-05 WO PCT/US1999/004967 patent/WO1999045379A2/fr not_active Ceased
- 1999-03-05 IL IL13775899A patent/IL137758A0/xx unknown
- 1999-03-05 EP EP99911174A patent/EP1068531B1/fr not_active Expired - Lifetime
- 1999-03-05 TR TR2001/01200T patent/TR200101200T2/xx unknown
2000
- 2000-09-05 NO NO20004433A patent/NO20004433L/no not_active Application Discontinuation
- 2000-09-27 BG BG104802A patent/BG104802A/bg unknown
2003
- 2003-10-16 AU AU2003255167A patent/AU2003255167A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TR200101129T2 (tr)	2002-06-21
CN100354627C (zh)	2007-12-12
AU2987899A (en)	1999-09-20
HUP0101959A3 (en)	2003-10-28
AU2003255167A1 (en)	2003-11-13
EP1068531A2 (fr)	2001-01-17
TR200002572T2 (tr)	2000-11-21
ATE375510T1 (de)	2007-10-15
IL137758A0 (en)	2001-10-31
DE69937292D1 (de)	2007-11-22
AU2887099A (en)	1999-09-20
WO1999045389A2 (fr)	1999-09-10
NO20004433L (no)	2000-11-06
WO1999045389A3 (fr)	2000-02-10
US6297021B1 (en)	2001-10-02
WO1999045379A3 (fr)	1999-11-25
JP2002506206A (ja)	2002-02-26
TR200101200T2 (tr)	2002-02-21
CN101221138A (zh)	2008-07-16
WO1999045379A2 (fr)	1999-09-10
NO20004433D0 (no)	2000-09-05
HUP0101959A2 (hu)	2001-09-28
TR200101127T2 (tr)	2002-06-21
EP1068531B1 (fr)	2007-10-10
CA2321968A1 (fr)	1999-09-10
KR20010041653A (ko)	2001-05-25
CN1299467A (zh)	2001-06-13
DE69937292T2 (de)	2008-07-03
PL343264A1 (en)	2001-07-30
AU767991B2 (en)	2003-11-27
BR9908563A (pt)	2000-11-21
SK13242000A3 (sk)	2001-03-12

Publication	Publication Date	Title
BG104802A (bg)	2001-04-30	Скрининг и конструиране на лиганди чрез рентгеноструктурен анализ
JP6195858B2 (ja)	2017-09-13	Ｔｆｐｉ阻害剤および使用方法
JP2020101548A (ja)	2020-07-02	同位体によりコード化されたレポーターによる多重検出
Patel et al.	2008	Discovering novel interactions at the nuclear pore complex using bead halo: a rapid method for detecting molecular interactions of high and low affinity at equilibrium
Rut et al.	2020	Substrate specificity profiling of SARS-CoV-2 main protease enables design of activity-based probes for patient-sample imaging
JP2000510454A (ja)	2000-08-15	カルシウム依存性結合タンパク質の改変されたリガンド
JP2000512737A (ja)	2000-09-26	試験管内蛍光偏光検定法
Benos et al.	1999	Gap junctions: molecular basis of cell communication in health and disease
Hayne et al.	2018	We FRET so you don’t have to: New models of the lipoprotein lipase dimer
Martin et al.	2021	Molecular architecture and modifications of full-length myocilin
US20020015943A1 (en)	2002-02-07	Assays, methods and means relating to the modulation of levels of nuclear beta-catenin
US20070140967A1 (en)	2007-06-21	Agents and methods for analyzing protein interactions
JP2003510053A (ja)	2003-03-18	ヘパラナーゼ蛋白質ファミリーの１種、ヘパラナーゼ−２
WO2001040268A2 (fr)	2001-06-07	Analogues beryllofluorides de polypeptides de phosphate d'acyle
US20030049678A1 (en)	2003-03-13	Ligand screening and design by X-ray crystallography
JP7011815B2 (ja)	2022-02-10	がんの判定方法
WO2002077623A1 (fr)	2002-10-03	Sonde pour visualiser la phosphorylation/dephosphorylation de proteines et procede de detection et de quantification de la phosphorylation/dephosphorylation de proteines
CZ20003246A3 (cs)	2001-03-14	Způsob vyhledávání a navrhování ligandů rentgenovou krystalografií
JP2021023208A (ja)	2021-02-22	蛍光ポリペプチドの変異体、及びその利用
Pepanian et al.	2024	In-depth characterization of Gαs protein activity by probing different guanine nucleotides
MXPA00008696A (en)	2001-07-31	Ligand screening and design by x-ray crystallography
JPWO2005094187A1 (ja)	2008-02-14	ラベル用物質とキメラ物質、これらの物質の作製方法、並びに該ラベル用物質を用いて生体物質を捕捉、構造解析又は／及び同定する方法
Mohamed et al.	2026	Molecular determinants underlying substrate receptor specificity of human CRL4B E3 ubiquitin ligase
Toul et al.	2026	Fibrin Selective Alteplase with Improved Thrombolysis and Inhibition Resistance Engineered by Rational Design
WO2025121411A1 (fr)	2025-06-12	Enzyme de modification dépendante d'une proximité modifiée